

Award Number:

W81XWH-12-1-0034

TITLE:

Novel Biomarker Discovery for Diagnostic and Therapeutic Strategies in Prostate Cancer

PRINCIPAL INVESTIGATOR:

Nanette H. Bishopric, M.D.

CONTRACTING ORGANIZATION:

University of Miami Miller School of Medicine
Miami, FL 33136

REPORT DATE: March 2013

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE			<i>Form Approved</i> <i>OMB No. 0704-0188</i>		
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE Mar 2013		2. REPORT TYPE Annual		3. DATES COVERED 1 March 2012 - 28 February 2013	
4. TITLE AND SUBTITLE Novel Biomarker Discovery for Diagnostic and Therapeutic Strategies in Prostate Cancer			5a. CONTRACT NUMBER		
			5b. GRANT NUMBER W81XWH-12-1-0034		
			5c. PROGRAM ELEMENT NUMBER		
6. AUTHOR(S) Nanette H. Bishopric, M.D. Betty Diamond E-Mail: n.bishopric@miami.edu			5d. PROJECT NUMBER		
			5e. TASK NUMBER		
			5f. WORK UNIT NUMBER		
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Miami Miller School of Medicine Miami, FL 33136			8. PERFORMING ORGANIZATION REPORT NUMBER		
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSOR/MONITOR'S ACRONYM(S)		
			11. SPONSOR/MONITOR'S REPORT NUMBER(S)		
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT The purpose of this grant is to identify, isolate and characterize high affinity aptamers that distinguish between prostate cancers that are likely to remain organ-confined and those with potential to metastasize. The scope of this pilot is to generate DNA aptamers that selectively react with a prostate cancer cell line that remains confined to the prostate (LNCaP) vs. a subpopulation of this cell line that has acquired the ability to metastasize aggressively, employing Cell-Selex and Aptamer-Facilitated Biomarker Discovery (AptaBiD) technology. <u>Major Findings and Progress:</u> (1) Non-metastatic LNCaP-Pro-5 cells and metastatic LNCaP-LN3 cells have been provided by Curtis Pettaway, M.D. Anderson Cancer Center, Houston, Texas. (2) Parental LNCaP cells have been obtained from American Type Culture Collection. (3) Phenotypic validation (aggressive vs. indolent growth) has been carried out on all cell lines using the Boyden Chamber assay. (4) DNA 40 bp aptamer libraries have been generated. (5) The first of 8 rounds of Cell-Selex has been initiated. (6) Plan for next-generation sequencing and bioinformatic analysis pathway has been established to yield desired phenotype-specific DNA aptamers. <u>Next steps</u> will include completion of Cell-Selex, NexGen sequencing and testing of DNA aptamer families on human clinical prostate cancer specimens.					
15. SUBJECT TERMS Prostate cancer, Cell-selex, metastasis, prognosis, biomarker, biopsy, screening, prediction, tissue microarray					
6. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			19b. TELEPHONE NUMBER (include area code)
			UU	9	

Table of Contents

	<u>Page</u>
Introduction.....	4
A. Introduction/summary	
B. Rationale	
Body.....	4
C. Progress on Scope of Work	
1) Task 1	
2) Task 2	
3) Task 3	
D. Remaining tasks	
1) Task 4	
2) Task 5	
3) Task 6	
4) Task 7	
E. Comments on the Timeline and Request for No-Cost Extension	
Key Research Accomplishments.....	6
Reportable Outcomes.....	7
Conclusion.....	7
F. Recommended changes to project	
G. Evaluation of the knowledge as a medical product	
References.....	9
Appendices.....	N/A

A. Introduction:

Prostate cancer (PC) is the most common non-skin cancer diagnosed in American men, with about 1 out of every 7 men receiving this diagnosis during his lifetime. The American Cancer Society estimates that in 2014, about 233,000 new cases of prostate cancer will be diagnosed, and about 29,480 men will die of prostate cancer. For many men, prostate cancer is an incidental diagnosis that will never require treatment or affect length or quality of life, while unfortunately, for other men, prostate cancer is a catastrophic, aggressive disease that can metastasize to other tissues of the body well before it becomes symptomatic. Thus, early and accurate detection of PC is essential to the treatment and cure of this disease, and to avoiding both under- and over-treatment. There is a critical need to search for novel tumor-specific markers that may enable more accurate detection of PC, predict tumor aggressiveness and serve as molecular targets for imaging and effective therapies. Our research objective is to utilize novel technologies to identify, isolate and characterize high affinity nucleic acid oligomers (aptamers) that distinguish between prostate cancers that are likely to remain organ-confined and those with potential to metastasize. We are employing Cell-SeleX [1-4] and Aptamer-Facilitated Biomarker Discovery (AptaBiD)[5] technologies to generate RNA aptamers that are selected to discriminate between PC cell lines that are either indolent or aggressive in their growth properties. In subsequent stages, these aptamers will be used A) to identify potential new biomarkers for indolent versus progressive prostate cancer, using affinity labeling, and B) for potential imaging applications including flow cytometry and fluorescence microscopy, in human prostate cancer microarrays.

B. Rationale:

It is critical to be able to identify the subset of prostate cancers that are likely to exhibit aggressive, metastasis-prone behavior. The highly metastasis-prone LNCaP-LN-3 prostate cancer cell was subcloned from a parental cell line (LNCaP) that almost never metastasizes[6, 7]. Thus these constitute a pair of cell lines that are genetically similar (derived from the same individual) but differ in metastatic potential. By identifying differences between these cell lines, we will be able to identify markers of aggressive behavior in prostate cancer.

C. Progress on Scope of Work

1. Task 1: Propagate non-metastatic (LNCaP-Pro-5) and metastatic (LNCaP-LN3) prostate cancer cell lines as well as control cell lines to initiate the DNA aptamer screening process. Status: Completed.

Task 1a. We have obtained LNCaP-Pro-5, LNCaP-LN3 and parental LNCaP cell lines from Dr. Pettaway of MD Anderson Cancer Center, Houston, TX[6] and American Type Culture Collection (<http://www.atcc.org>) respectively.

Task 1b. We have propagated and tested these cells for growth properties *in vitro* to confirm that they represent distinctive indolent (LNCaP and LNCaP-Pro-5) and aggressive (LNCaP-LN3) phenotypes. We have used several measures of aggressiveness: tumor doubling time, growth and invasiveness in 1- (scratch assay) and 2- dimensional (Boyden chamber) assays. These assays have indicated that there is little difference between the two indolent cell lines, but substantial difference between these two and the LNCaP-LN3 line, which is able to aggressively metastasize from the prostate *in vivo* (Pettaway ref). We also have propagated multiple controls: MCF-7, MCF-10A, MCF-12A, MDA-MB-231, HUVEC and HMEC cell lines, and primary rat and human fibroblasts, which will be utilized in the negative selection steps. By subtracting against these control cell types, we will eliminate aptamers that cross-react with non-prostate cancer cell types.

2. Task 2: Prepare dual-labeled, randomized aptamer pool for AptaBiD selection process. Status: Completed.

Task 2a. We previously generated and tested a pool of dual-labeled, 40-mer DNA aptamers (10^{33} randomized sequences; common 5' and 3' sequences for sequencing; biotinylated and labeled with Alexa Fluor 647). Following departure of the original PI of this project immediately after the start date, we have been re-assessing the strategic aspects of the project in light of the recommendations of local investigators with expertise in area. While we still retain this DNA aptamer library, we now have determined that RNA aptamers have practical and strategic advantages for our project [8-10].

Task 2b. We have obtained a second, RNA aptamer library from a collaborator (Dr. Paolo Serafini, University of Miami), thus its use will not add to the cost of the project. We therefore are currently in the process of performing Cell-SeleX against a fluorinated RNA aptamer library with our indolent and aggressive LNCaP cells. Fluorination of the

nucleic acid backbone stabilizes the RNA aptamers against RNase degradation.

3. Task 3: Perform first round of “positive” RNA aptamer selection using the metastatic (LNCaP-LN3) prostate cancer cell line. Status: we expect this step to be completed in 1 week (April 2014).

Task 3a: Initial positive selection. As noted above, first-round selection is underway. Because the issue of clinical detection is most critical with respect to metastasis-prone tumors, we have opted to focus initially on a screen in which LNCaP-LN3 (aggressive) cells are used as the “positive” selection. In this approach, metastasis-prone LNCaP-LN3 cells are incubated with the complete RNA aptamer pool (30 minutes at 4°C) to initially select for RNA aptamers that interact with more aggressive prostate cancer cells. Unbound RNA aptamers are removed by media aspiration and washing in PBS.

Task 3b: Recovery of positively selected aptamers. Cells are heated (95°C for 5 minutes) to remove bound RNA aptamers.

Task 3c: Amplification of recovered aptamers. Released organ-confined or metastatic prostate cancer cell specific RNA aptamers are amplified via polymerase chain reaction (PCR) to expand this positively selected population.

D. Further tasks to be accomplished in the remaining funding period

1. Task 4: Negative selection. We will perform the first round of “negative” RNA aptamer selection using parental LNCaP cells, HPECs and non-prostate control cell lines with the enriched RNA aptamers pools (Timeframe = 1 month; April-May 2014).

Task 4a: Enriched metastatic prostate cell-specific RNA aptamer pools (generated in Task 3) will be incubated with cellular pools containing parental LNCaP cells, HPEC and non-prostate cells (30 minutes at 4°C).

Task 4b: Bound aptamers will be removed by centrifugation of the control cells to which they are bound. RNA aptamers that do not bind to these cells will be recovered in the cell supernatant and retained. The retained, “subtracted” RNA aptamer pool will be enriched for species that bind to metastatic LNCaP-LN-3 cells but not control cells.

Task 4c: The subtracted aptamer pool will be amplified by PCR.

2. Task 5: Serial positive and negative selection cycles. The positive and negative selection of RNA aptamers that bind either organ-confined or metastatic LNCaP cells will be repeated for 8 cycles. Sub-tasks outlined in Tasks 3 and 4 will be repeated 8x each. (Timeframe = 2 months; anticipated completion July 2012)

3. Task 6: AptaBiD Biomarker discovery. (see E. Recommendations, below). Our original scope of work calls for the use of aggressive PC-specific RNA aptamer pools to identify unique biomarkers to discriminate between organ-confined and metastasis-prone prostate cancer (Timeframe = 4 months; November 2014).

Task 6a: Binding of aptamers to biomarkers on PC cells. RNA aptamer pools, generated at the conclusion of task 5, will be labeled with biotin. Metastatic LNCaP-LN3 cells will be incubated with the biotin-labeled RNA aptamer pools (30 minutes at 4°C). Parental LNCaP and non-metastatic sister clone LNCaP-Pro-5 cells will be used as negative controls.

Task 6b: Capture of cell-bound aptamers. Following washing and centrifugation, aptamer-bound cells will be incubated with streptavidin-labeled magnetic beads (15 minutes at 4°C) that will bind with high affinity to the biotinylated RNA aptamers on the cells. Cell-RNA aptamer-magnetic bead complexes are then captured via a magnetic stand and washed with PBS.

Task 6c: Recovery of specific aptamer-bound proteins. Captured cells are lysed (PBS+Mg with 0.1%v/v Triton X-100) for 10 minutes at 4°C. This releases biomarker protein-RNA aptamer-magnetic bead complexes from cell structures. The biomarker-containing complexes are captured on a magnetic stand and washed with cold PBS. Biomarker peptides are dissociated from the aptamer/bead complex using 8M urea (30 minutes at 0°C).

Task 6d: Purification of biomarker peptides. The biomarker peptide mixture is extracted and purified using a ready-to-go pipette tip filled with C18 spherical silica reversed phase material (ZipTipC18 – Millipore).

Task 6e: Identification of biomarker proteins. Protein sequencing is performed by liquid chromatography and mass spectroscopy. When completed, this task will identify proteins specifically bound by the metastatic LNCaP-LN3 RNA aptamer pools but not by non-metastatic LNCaP parental and -Pro-5 subclones.

4. Task 7: Biomarker validation in clinical specimens. The potential biomarkers (both RNA aptamers and aptamer-identified proteins (AptaBIPs) for aggressive prostate cancer yielded in Task 6 will be examined across other prostate cancer cell lines as well as in banked tumor specimens. Direct reactivity of these aptamers and/or reactivity of antibodies against AptaBIPs in these additional PC types will be correlated with associated clinical data on prostate cancer progression and outcome. The ability of these new prostate cancer biomarkers to discriminate between progressive and indolent disease will be evaluated using fluorescent microscopy and immunohistochemistry with prostate cancer tissue microarrays (TMAs) (Timeframe = 4 months; end-February 2015).

Task 7a: Assembly of PC resources to be screened. Include 5 internal prostate TMAs (n=48 cores/slide including BPH (n=12), normal tissues (n=8), organ-confined prostate cancer (n=20) and several metastatic prostate tumors (n=8)) and 6 additional prostate TMAs (n=64 cores/slide) with non-prostate controls and prostate cancer cell lines will be screened for each novel biomarker. In addition, we have 163 sections of prostate samples including BPH, normal adjacent tissue, organ-confined tumors and a limited number of metastatic tumor sections. These TMAs and tissues sections will be analyzed for the presence of candidate biomarkers identified in Task 6.

Task 7b: Development of IHC strategy for biomarker identification. Where feasible, antibodies recognizing candidate biomarkers will be purchased and evaluated for marker detection using IHC. This will be completed at the Analytical Imaging Core Facility. Biomarker expression and distribution will be correlated to prostate cancer stage and progression as well as clinical outcome where known.

Task 7c: Reactivity of RNA aptamers with PC samples. Similar TMAs and sections will be exposed to Alexa Fluor 647-labeled metastatic RNA aptamer pools to evaluate specificity of these selected RNA aptamers as well as their potential use in imaging applications via fluorescent microscopy.

E. Comments on the Timeline and Request for No-Cost Extension

The original PI departed the institution in February 2012, and we were granted a change of management to the current PI (myself). In June 2012, after overcoming some unavoidable transition-related delays, a technician with expertise in aptamer library screening was hired to assist with the work and the cell lines were obtained and optimal growth conditions established (Task 1, September-October 2012). A new DNA aptamer library was synthesized (September 2012, Task 2). The cell line growth properties were validated in culture (Task 1b) and the protocol for Cell-Selelex was established (November 2012).

In December 2012 the technician assisting with the project departed to work in a clinical laboratory. Because of hiring freezes in place at that time at the University, we anticipated that it would take some time to obtain a replacement. We requested a NCE at that time that would allow us to continue the project at no cost after the end of the grant period (end February 2013). The combination of the protracted hiring freeze (which remained in place throughout 2013), the government shutdown in October 2013, chronic difficulty communicating to appropriate entities within the DOD, and a lack of communication from DOD regarding granting of the NCE, meant that the funds to hire a replacement were never expended. This has resulted in an additional extremely unfortunate delay in progress.

In March 2014 we were able to hire a talented individual (S. Speransky) using funds from another project and we have re-initiated work on this important grant, achieving Task 3 in collaboration with Dr. Paolo Serafini. We have been asked to submit this progress report by the DOD in order to allow consideration of further work on the project. If the remaining funds are extended, we expect to complete work on or before the end of the current grant anniversary (March 1 2015).

Key Research Accomplishments

- We have obtained LNCaP-LN3 (aggressive, metastasis-prone), LNCaP-Pro-5 and parental LNCaP cell lines.

- We have propagated and tested these cells for growth properties *in vitro* to confirm that they represent distinctive indolent (LNCaP and LNCaP-Pro-5) and aggressive (LNCaP-LN3) phenotypes, using tumor doubling time, growth and invasiveness in 1- (scratch assay) and 2- dimensional (Boyden chamber) assays.
- We have propagated multiple control cell lines as noted in Task 1.
- We have refined, updated and validated the aptamer selection protocol in keeping with recent literature in this area.
- We have commenced Cell-SeleX against a fluorinated RNA aptamer library with the indicated indolent and aggressive LNCaP cells described above.

Reportable Outcomes:

While the project is still at early stages, here is a summary of the outcomes we expect to report at the conclusion of this effort:

- **Milestone #1.** The process outlined in **Task 1-5** will generate RNA aptamers that interact specifically with aggressive LNCaP-LN-3 prostate cancer cells and not with indolent parental LN-CaP cells. The use of living prostate cancer cells allows us to select for aptamers that bind to native proteins on the surface or interior of unfixed, fresh tumor tissue.
- **Milestone #2.** Successful completion of **Task 6** will identify the DNA sequence or protein properties of one or more RNA aptamer species and/or biomarkers that distinguish between prostate cancers that are more likely to remain organ-confined vs. those that are likely to metastasize elsewhere in the body.
- **Milestone #3:** At the completion of **Task 7**, initial feasibility and future validation of these new biomarkers will have been achieved. In addition, the application of selected RNA aptamers and aptamer pools as an imaging reagent for early and advanced disease will have been explored.

Conclusion

This project is no less important than when it was originally proposed to the DOD, and the tasks remain novel and likely to yield important tools for treatment of prostate cancer, the most common cancer affecting men in this country. Our updates to the scope of work and the proposed technology have enhanced and streamlined the project and added value to the proposed outcomes. Completing this study with a small group of unique, sequence-defined RNA aptamers that react with aggressive PC will represent the generation of important new tools for the diagnosis and therapeutic management of prostate cancer.

F. Recommended changes or future work to better address the research topic:

F1. Next-Generation Sequencing in Task 6. Our original scope of work called for characterizing our metastasis-predictive aptamers by determining the unique proteins bound by these aptamers as outlined in Task 6. Based on recent technical improvements, accessibility, speed and cost-effectiveness of sequencing technology, we recommend next-generation sequencing to directly identify the aptamers themselves, to verify their nucleotide sequence relationships, and to allow us to focus on aptamer-specific PC detection in Task 7c of the proposal. We recommend replacement of Tasks 6a-6e as follows:

- **New Task 6a.** Perform next-generation sequencing on RNA aptamer pools after cycle 8 (replicate samples x 2), using Illumina HiSeq 2000 sequence detection system. Estimated timeline: 2 weeks.

- **New Task 6b.** Perform bioinformatic analysis on sequence information to identify core sequence motifs of selected RNA aptamers. Estimated timeline: 5-6 weeks.

F2. Proceeding directly from Task 6 to Task 7c. In this approach the aptamers themselves serve as the reagents for identification of aggressive prostate cancer. This can be done instead of, or prioritized ahead of, the protein discovery steps previously proposed for Task 6. We anticipate considerable savings in time and cost as a result. Cost savings are realized at several levels:

- Fewer rounds of positive and negative selection would be required in Task 5 (we have already reduced cycles from 10 to 8 in our revised SOP based on this assumption.)
- We estimate that the 4 months of labor required to achieve protein isolation, purification and identification by mass spectroscopy could be replaced by 1-2 months of bioinformatic analysis of the sequence data recovered at the end of Task 5.
- Because the labeled aptamers themselves serve as reagents for imaging, the need for development or purchase of antibodies against biomarker proteins as described in Tasks 7a-b is obviated.
- Based on our selection protocol, the aptamers and aptamer pools will selectively bind to PC cells prone to aggressive growth and metastasis even in the absence of information about the specific protein biomarkers to which they are bound. Thus one is not limited to the universe of known proteins or protein complexes. This is also useful when antibodies are lacking for known proteins (see above).
- *A priori* validation of the RNA aptamers against other prostate cancer cell lines and tumor microarrays is likely to yield a limited number, possibly only 1-2 species, that are truly discriminatory for aggressive tumor growth. Eventually, identification of the protein targets of this small number of highly validated aptamers will be considerably less complex and more revealing of biologically relevant differences between indolent and progressive PC.

G. Evaluation of the knowledge as a scientific or medical product

On successful completion, the products of this project should include the following reagents which will have potential scientific utility and medical imaging and diagnostic uses, as shown by others [4, 9, 11, 12]:

- A pool of dual-labeled RNA aptamers able to discriminate between indolent and aggressive prostate cancer.
- One or more sequence-defined RNA aptamers able to discriminate between indolent and aggressive prostate cancer.
- A list of potential novel protein biomarkers for aggressive vs. indolent prostate cancer.
- A novel set of aptamer-based reagents for imaging applications via fluorescent microscopy.

The foundation for the identification and validation of critical biomarkers that may be involved in delineating indolent disease from aggressive or advanced prostate cancer is a critical challenge and focus area of the PCRCP and would be addressed by the experiments outlined in this proposal.

REFERENCES

1. Shangguan D, Cao ZC, Li Y, Tan W (2007) Aptamers evolved from cultured cancer cells reveal molecular differences of cancer cells in patient samples. *Clin Chem* 53(6): 1153-1155
2. Guo KT, Ziemer G, Paul A, Wendel HP (2008) CELL-SELEX: Novel perspectives of aptamer-based therapeutics. *Int J Mol Sci* 9(4): 668-678
3. Kim Y, Liu C, Tan W (2009) Aptamers generated by Cell SELEX for biomarker discovery. *Biomark Med* 3(2): 193-202
4. Fang X, Tan W (2010) Aptamers generated from cell-SELEX for molecular medicine: a chemical biology approach. *Acc Chem Res* 43(1): 48-57
5. Berezovski MV, Lechmann M, Musheev MU, Mak TW, Krylov SN (2008) Aptamer-facilitated biomarker discovery (AptaBiD). *J Am Chem Soc* 130(28): 9137-9143
6. Pettaway CA, Pathak S, Greene G, Ramirez E, Wilson MR, Killion JJ, Fidler IJ (1996) Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. *Clin Cancer Res* 2(9): 1627-1636
7. McConkey DJ, Greene G, Pettaway CA (1996) Apoptosis resistance increases with metastatic potential in cells of the human LNCaP prostate carcinoma line. *Cancer Res* 56(24): 5594-5599
8. Ulrich H (2006) RNA aptamers: from basic science towards therapy. *Handb Exp Pharmacol*(173): 305-326
9. Thiel KW, Giangrande PH (2009) Therapeutic applications of DNA and RNA aptamers. *Oligonucleotides* 19(3): 209-222
10. Aquino-Jarquín G, Toscano-Garibay JD (2011) RNA aptamer evolution: two decades of SELEction. *Int J Mol Sci* 12(12): 9155-9171
11. Zhou J, Rossi JJ (2009) The therapeutic potential of cell-internalizing aptamers. *Curr Top Med Chem* 9(12): 1144-1157
12. Sundaram P, Kurniawan H, Byrne ME, Wower J (2013) Therapeutic RNA aptamers in clinical trials. *Eur J Pharm Sci* 48(1-2): 259-271